Best Oncology Power Hour Podcasts (2024)

1
The Impact of Advocacy on Healthcare

1d ago

—

Guest: Ashley L. Sumrall, MD If we want to ensure that we and our patients have healthcare when we’re older and it continues to be available, it’s important to take a stand and be a part of advocacy work. There are multiple ways to get involved, and it’s not as intimidating as someone might think, so to share some of these strategies and the impact…

1
The Power of Patient Advocacy in Daily Clinical Practice

1d ago

—

Guest: Ashley L. Sumrall, MD Advocacy is rooted in patients telling their stories, and every patient can be an advocate to help and allow others to hear about their experience. This has also helped clinicians get the medicine they need for their patients. Dive in to hear how you can incorporate advocacy strategies into your practice with Dr. Ashley…

1
Updates on New Technologies and Imaging Agents in Healthcare

1d ago

—

Guest: Tyler J Bradshaw, PhD In recent years, doctors have become interested in how large language models and AI technologies could potentially improve radiology overall. Even though these technologies are still in the beginning stages of being used in medicine, eventually doctors hope to show what impact they could have on patients. To learn more …

1
Practical Applications for Quality Improvement in Myelofibrosis Management: A Video Brief on Lessons Learned

16h ago

—

Host: Joseph Kim, MD, MPH This video brief will discuss quality improvement in myelofibrosis management. To highlight ways to improve care for patients with both primary and secondary myelofibrosis, we’ll examine the experiences of two cancer centers that engaged in quality improvement programs. Molecular Testing Symptom Assessment Prognostic Risk …

1
A Pre-Conference Perspective of SNMMI 2024

1d ago

—

Tune in ahead of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting in Toronto for a preview of what to expect with Dr. Munir Ghesani, Chief Medical Officer and the Medical Director at United Theranostics in Princeton, New Jersey.

1
An Introduction to Squamous Cell Carcinoma of the Head and Neck

6d ago

—

Guest: Lori J. Wirth, MD Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston. References: Gormley M, et al. Br …

1
EMERALD Trial: An Analysis of Key Biomarkers and Patient Subgroups

8d ago

—

Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocr…

1
Poster Pearl: A 2-Biomarker Class MCED Test Delivers High Specificity and Sensitivity

16d ago

—

Host: Brian P. McDonough, MD, FAAFP Guest: Frank Diehl, PhD A poster presented at the 2024 American Association for Cancer Research Annual Meeting showcased findings from the ASCEND 2 study, which examined the performance of a multi-cancer early detection (MCED) test design that included methylation and protein biomarkers. The study found that this…

1
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer

1M ago

—

Host: Javier Cortes, MD, PhD Guest: Komal Jhaveri, MD, FACP The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optima…

1
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC

1M ago

—

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

1
Managing Immune-Related Adverse Events With Immunotherapies

1M ago

—

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

1
Overcoming Barriers to Equitable Care in HNSCC

1M ago

—

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

1
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens

1M ago

—

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

1
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence

1M ago

—

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunother…

1
Indications to Switch Therapies for Myelofibrosis Patients

2M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Justin Arnall, PharmD, BCOP, CPP Guest: Jerry L. Spivak MD, MACP While managing patients with myelofibrosis, there are certain indications that it may be time to switch therapies. And working with your patient will help with a timely and seamless transition. To learn more about these best practices, j…

1
Managing Myelofibrosis with a Patient-Centered Approach

2M ago

—

Guest: Justin Arnall, PharmD, BCOP, CPP Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jerry L. Spivak MD, MACP After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to select the best intervention. Having a personalized approach to treatment and management could have a beneficial impact on the ove…

1
Anemia and Myelofibrosis: Optimizing Diagnosis, Treatment, and Management Strategies

2M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Prithviraj Bose, MD Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, div…

1
Exploring the Significant Presence of Anemia in Myelofibrosis

2M ago

—

Host: Jennifer Caudle, DO Guest: Jason Tremblay Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with ensuring we’re using the best therapeutic strategies. Learn more with Dr. Jennifer Caudle as she speaks with Dr. Douglas Tremb…

1
Navigating Myelofibrosis Treatment Complexities to Optimize Care

2M ago

—

Host: Jennifer Caudle, DO Guest: Jason Tremblay Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even be rare to see patients who experience myelofibrosis the same. So to take a deep dive into the treatment paradigm of this di…

1
Maximizing B-Cell Lymphoma Outcomes with CAR T-Cell Therapy and Personalized Care

2M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tara Graff, DO, MS The therapeutic landscape for relapsed or refractory B-cell lymphoma has greatly evolved in the past several years, with CAR T-cell therapy and personalized care becoming increasingly important in the second-line setting. Joining Dr. Charles Turck to discuss how CAR T-cell therapy a…

1
Managing B-Cell Lymphomas in the Second-Line Setting: The Role of CAR T-Cell Therapy

2M ago

—

Host: Jennifer Caudle, DO Guest: Sarah Rutherford, MD Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell th…

1
B-Cell Lymphoma Care: Overcoming Challenges in the Second-Line Setting

2M ago

—

Guest: Matthew Lunning, DO, FACP It’s not uncommon for patients with B-cell lymphoma to have relapsed or refractory disease, making it essential to know how to approach their second-line treatment. Unfortunately, many challenges and unmet needs exist in this setting, which is why Dr. Matthew Lunning is here to discuss those challenges as well as th…

1
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights

3M ago

—

Guest: Alan Bryce, MD Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.…

1
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib

4M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neeraj Agarwal, MD, FASCO TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a …

1
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access

4M ago

—

Host: Rishi Sekar, MD A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in…

1
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care

4M ago

—

Host: Jacob Sands, MD Guest: Aakesh Desai, MD, MPH According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to optimize the care of patients with non-small cell lung cancer. Tune in to hear Dr. Jacob Sands explore the key findings with Dr…

1
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification

4M ago

—

Host: Zachery Reichert MD, PhD If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who had pain when entering the study, 45 percent had their pain improved with chemotherapy. Dive more into the findings with D…

1
Emerging Strategies in Multi-Cancer Early Detection

5M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tomasz Beer, MD, FACP Guest: Betsy O'Donnell, MD Recent estimates show that only 14 percent of cancers are detected through routine screening, meaning the majority of patients are diagnosed after the onset of clinical symptoms. But multi-cancer early detection (MCED) tests offer the opportunity to pot…

1
The Necessity of a Multidisciplinary Approach Through the mCRPC Treatment Journey

5M ago

—

Guest: Jessica E. Hawley M.D. M.S. For patients who start out with hormone sensitive prostate cancer, there's a period of time where the prostate cancer cells are responsive to suppressing testosterone production. So there’s a nice disease response early in that time period after diagnosis and when initial treatment has begun, but how long is each …

1
Treating High-Risk Biochemically Recurrent Prostate Cancer: An Update from ASCO-GU

5M ago

—

Host: Neal Shore, MD Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalut…

1
ASCO GU 2024: Reviewing Updated Practice Guidelines for Prostate Cancer

5M ago

—

Guest: Jessica E. Hawley M.D. M.S. The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the Univ…

1
Prostate Cancer Care: Overcoming Challenges in Delivering Germline Testing to Veterans

5M ago

—

Host: Daniel Kwon, MD Between patient anxiety and insurance implications, there are several challenges associated with delivering germline testing to veterans with advanced prostate cancer. Learn more about these challenges and proposed solutions with Dr. Daniel Kwon, who presented the “Challenges in Patient-Centered Germline Testing Delivery for V…

1
Treating Patients with NSCLC: Decision-Making and Surgical Considerations

5M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ravi Rajaram, MD, MSC NEOSTAR is a phase 2 trial with multiple arms looking at different combination therapies in the setting of resectable lung cancer. So what results were found from this study? Join in as Dr. Charles Turck discusses this further with Dr. Ravi Rajaram, Assistant Professor and the Cl…

1
NSCLC Care: Evaluating Durvalumab in the First-Line Setting

6M ago

—

Host: Jacob Sands, MD Guest: Liza Villaruz, MD According to a recent study, the immune checkpoint inhibitor durvalumab is not only considered safe, but it may also offer overall survival benefits for individuals with advanced or metastatic non-small cell lung cancer (NSCLC) and restricted performance status. Here to talk about this research are Dr.…

1
How Do We Implement ANNEXXa-I Into Our Clinical Practice?

6M ago

—

Host: Adam Brufsky, MD, PhD Host: Christopher M. Gallagher, MD Join us as expert faculty, Dr. Adam Brufsky and Dr. Christopher Gallagher, discuss the qualities of credible real world evidence (RWE) publications, application of CDK4/6 inhibitor RWE in hormone receptor positive metastatic breast cancer, and integrating RWE into everyday clinical deci…

1
SABCS 2023: A Look into New Research for Inflammatory Breast Cancer

6M ago

—

Guest: Filipa Lynce, MD It’s very common for patients with inflammatory breast cancer (IBC) to present with no underlying palpable mass, which may cause some challenges for clinicians and patients. So what are some unique challenges associated with surgery in IBC and the risks of deescalating? Join Dr. Filipa Lynce, Director of the Inflammatory Bre…

1
Inflammatory Breast Cancer: A New Scoring System Proposed

6M ago

—

Guest: Filipa Lynce, MD Inflammatory breast cancer (IBC) is a rare disease that represents about two to three percent of all breast cancers and is challenging to diagnose. To improve diagnosis, researchers are working to validate a new proposed scoring system. Review the current research with Dr. Flipia Lynce, Director of the Inflammatory Breast Ca…

1
A Look at What’s New in Invasive Lobular Carcinoma

6M ago

—

Host: Pavani Chalasani, MD, MPH Guest: Jason A. Mouabbi, MD Invasive lobular carcinoma (ILC) is an understudied subtype that occurs in about 10 to 15 percent of breast cancer patients and is known to be difficult to detect by imaging. So how do we approach diagnosing and treating this subtype? Dr. Pavani Chalasani is joined by Dr. Jason Mouabbi, As…

1
When Breast Cancer Spreads to the Brain: Diagnosis and Treatment Strategies

7M ago

—

Host: Pavani Chalasani, MD, MPH Guest: Jose Pablo Leone, MD Breast cancer is the second most common cause of brain metastases. Given this prevalence, how can we identify the early signs and symptoms and treat patients with metastatic breast cancer accordingly? Here to dive further into this topic with Dr. Pavani Chalasani is Dr. Jose Pablo Leone, D…

1
Examining the Economic Impacts of Biosimilars in Oncology

8M ago

—

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Sophia Humphreys, PharmD, MHA, BCBBS Not only can biosimilars impact the health of our patients with cancer, but they can also contribute to cost savings for the healthcare system as a whole. Here to dive further into the economic impacts of biosimilars in the oncology space with Dr. Mary…

1
Approaches to Utilizing Bone-targeting Therapies in mBC

9M ago

—

Host: Pavani Chalasani, MD, MPH Guest: Gabriel N. Hortobagyi, MD Bone metastases are the most frequent site of metastatic spread for breast cancer, especially for the luminal subtypes, which are the most frequent types of breast cancer. Here to dive further into these therapies with Dr. Pavani Chalasani is Dr. Gabriel Hortobagyi, Professor of Medic…

1
Advances in Early-Stage Breast Cancer Treatment: A Recap of the NATALEE Trial

10M ago

—

Host: Pavani Chalasani, MD, MPH Guest: Nick McAndrew, MD, MSCE How can ribociclib plus endocrine therapy help reduce recurrence in early breast cancer? That’s the exact question the NATALEE trial sought to answer, and here to discuss the results with Dr. Pavani Chalasani is Dr. Nicholas McAndrew, Assistant Professor in the Division of Hematology an…

1
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies

10M ago

—

Host: Jacob Sands, MD Guest: Jia Luo, MD NUT carcinoma is a rare, aggressive form of cancer that’s highly resistant to therapy and has no defined standard treatment. Joining Dr. Jacob Sands to discuss the best diagnostic and treatment strategies for NUT carcinoma is Dr. Jia Luo, medical oncologist at Dana-Farber Cancer Institute and an Instructor o…

1
Diving into the Efficacy & Tolerability of mBC Treatment

10M ago

—

Host: Pavani Chalasani, MD, MPH Guest: Colleen Bohnenkamp, PharmD, BCPS, BCOP In a recent study, investigators conducted a randomized trial to compare the efficacy and tolerability of a fixed dose of an oral chemotherapy drug on a 7/7 schedule. Here with Dr. Pavani Chalasani to discuss the results from the X-7/7 trial is Dr. Colleen Bohnenkamp, Onc…

1
Keeping Pace in Hematologic Malignancies: 2023 Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes

11M ago

—

Host: Harry Paul Erba, MD, PhD Guest: Courtney DiNardo, MD Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as…

1
Reducing the Rise of Uterine Cancer in the United States

11M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Richard T. Penson, MD, MRCP Uterine cancer is the most common type of gynecologic malignancy in the United States, and disease mortality is on the rise. What do we need to know from recent studies to diagnose patients earlier? Take a deep dive with Dr. Charles Turck as he is joined by Dr. Richard Pens…

1
Investigating a Therapy for Brain Metastases: A Growing Problem

12M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Priscilla Brastianos, MD Brain metastases are the most common type of brain tumor, and unfortunately, prognosis is still limited and can range from a few months to a few years. However, the next-step approaches look promising for improving patient outcomes. Dive in with Dr. Charles Turck as he speaks …

1
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC

1y ago

—

Guest: Vivek Subbiah, MD This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.…

1
Impact of Infertility & Elective Fertility Among Female Oncologists

1y ago

—

Guest: Emily MacDuffie, MD A recent survey conducted by physicians at Penn Medicine found that one-third of female oncologists reported experiencing infertility. Join Dr. Emily Macduffie, Radiation Oncology Resident Physician at Penn Medicine, as she speaks about potential solutions related to infertility for women in medicine based on her 2023 ASC…

1
Combating the Complexities of Cancer Care During Pregnancy

1y ago

—

Guest: Alison Wakoff Loren, MD, MSCE Cancer occurs in approximately 1 in every 1,000 pregnant patients and requires complex solutions from a multidisciplinary team. Learn more about the expanding management options for these patients with Dr. Alison Loren, Chief of the Division of Hematology and Oncology at the University of Pennsylvania Perelman S…

Podcasts Worth a Listen

Oncology Power Hour Podcasts

Podcasts Worth a Listen

Quick Reference Guide